The Latest Cardiac and Vascular News
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that results from the CONVERGE IDE trial have been accepted for presentation in the late-breaking abstract sessions at the Heart Rhythm Society (HRS) Scientific Sessions. The abstract will […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the first quarter 2020 and provided updates in response to the COVID-19 pandemic. “Through these challenging times, our first priority continues to be the […]
2019 Worldwide revenue of $230.8 million – an increase of 14.5% year over year 2019 U.S. revenue of $185.8 million – an increase of 14.6% year over year 2019 International revenue of $45.0 million – an increase of 13.9% year over year MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2019 and provided 2020 financial guidance. Preliminary, unaudited revenue for fourth quarter 2019 is expected to be approximately […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the successful completion of patient enrollment in the aMAZE™ clinical trial. In addition, the company announced that it has received approval from the Food and Drug Administration […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Karen Prange and Daniel Florin have been named to its Board of Directors. Ms. Prange was most recently Executive Vice President and Chief Executive Officer for the Global […]
Clinical evidence demonstrates that AtriClip® devices exclude and electrically isolate the left atrial appendage MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of […]
Acquisition Expands Addressable Market Opportunity and Complements Offerings for the Treatment of Atrial Fibrillation Announces Updates to 2019 Outlook Conference Call Monday, August 12th at 8:30am ET MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that […]
Worldwide revenue of $58.9 million – an increase of 13.7% year over year U.S. revenue of $47.2 million – an increase of 15.5% year over year International revenue of $11.7 million – an increase of 7.0% year over year July 30, 2019 04:02 PM Eastern Daylight Time MASON, Ohio–(BUSINESS WIRE)–AtriCure, […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2019 financial results on Tuesday, July 30, 2019. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, […]
